25576061|t|Insulin resistance predicts medial temporal hypermetabolism in mild cognitive impairment conversion to Alzheimer disease.
25576061|a|Alzheimer disease (AD) is characterized by progressive hypometabolism on [(18)F]-fluorodeoxyglucose positron emission tomography (FDG-PET) scans. Peripheral insulin resistance (IR) increases AD risk. No studies have examined associations between FDG metabolism and IR in mild cognitive impairment (MCI) and AD, as well as MCI conversion to AD. We studied 26 cognitively normal (CN), 194 MCI (39 MCI-progressors, 148 MCI-stable, 2 years after baseline), and 60 AD subjects with baseline FDG-PET from the Alzheimer's Disease Neuroimaging Initiative. Mean FDG metabolism was derived for AD-vulnerable regions of interest (ROIs), including lateral parietal and posteromedial cortices, medial temporal lobe (MTL), hippocampus, and ventral prefrontal cortices (vPFC), as well as postcentral gyrus and global cerebrum control regions. The homeostasis model assessment of IR (HOMA-IR) was used to measure IR. For AD, higher HOMA-IR predicted lower FDG in all ROIs. For MCI-progressors, higher HOMA-IR predicted higher FDG in the MTL and hippocampus. Control regions showed no associations. Higher HOMA-IR predicted hypermetabolism in MCI-progressors and hypometabolism in AD in medial temporal regions. Future longitudinal studies should examine the pathophysiologic significance of the shift from MTL hyper- to hypometabolism associated with IR.
25576061	0	18	Insulin resistance	Disease	MESH:D007333
25576061	44	59	hypermetabolism	Disease	MESH:C565498
25576061	68	88	cognitive impairment	Disease	MESH:D003072
25576061	103	120	Alzheimer disease	Disease	MESH:D000544
25576061	122	139	Alzheimer disease	Disease	MESH:D000544
25576061	141	143	AD	Disease	MESH:D000544
25576061	177	191	hypometabolism	Disease	
25576061	195	221	[(18)F]-fluorodeoxyglucose	Chemical	MESH:D019788
25576061	252	255	FDG	Chemical	MESH:D019788
25576061	279	297	insulin resistance	Disease	MESH:D007333
25576061	299	301	IR	Disease	MESH:D007333
25576061	313	315	AD	Disease	MESH:D000544
25576061	368	371	FDG	Chemical	MESH:D019788
25576061	387	389	IR	Disease	MESH:D007333
25576061	398	418	cognitive impairment	Disease	MESH:D003072
25576061	420	423	MCI	Disease	MESH:D060825
25576061	429	431	AD	Disease	MESH:D000544
25576061	444	447	MCI	Disease	MESH:D060825
25576061	462	464	AD	Disease	MESH:D000544
25576061	509	512	MCI	Disease	MESH:D060825
25576061	517	520	MCI	Disease	MESH:D060825
25576061	538	541	MCI	Disease	MESH:D060825
25576061	582	584	AD	Disease	MESH:D000544
25576061	608	611	FDG	Chemical	MESH:D019788
25576061	625	644	Alzheimer's Disease	Disease	MESH:D000544
25576061	675	678	FDG	Chemical	MESH:D019788
25576061	706	708	AD	Disease	MESH:D000544
25576061	986	988	IR	Disease	MESH:D007333
25576061	995	997	IR	Disease	MESH:D007333
25576061	1019	1021	IR	Disease	MESH:D007333
25576061	1027	1029	AD	Disease	MESH:D000544
25576061	1043	1045	IR	Disease	MESH:D007333
25576061	1062	1065	FDG	Chemical	MESH:D019788
25576061	1083	1086	MCI	Disease	MESH:D060825
25576061	1112	1114	IR	Disease	MESH:D007333
25576061	1132	1135	FDG	Chemical	MESH:D019788
25576061	1216	1218	IR	Disease	MESH:D007333
25576061	1229	1244	hypermetabolism	Disease	MESH:C565498
25576061	1248	1251	MCI	Disease	MESH:D060825
25576061	1268	1282	hypometabolism	Disease	
25576061	1286	1288	AD	Disease	MESH:D000544
25576061	1421	1440	- to hypometabolism	Disease	
25576061	1457	1459	IR	Disease	MESH:D007333
25576061	Negative_Correlation	MESH:D019788	MESH:D000544
25576061	Negative_Correlation	MESH:D019788	MESH:D007333

